Hyperactivity of PI3K/Akt/mTOR/S6 signaling has been found in the dermal fibroblasts of SSc patients [1] and inhibition of this pathway leads to significant protection against TGFβ-induced fibroblast growth in an SSc mouse model [1,5,6]. Here, AKT1 is linked to systemic sclerosis.